Name: Azetukalner (XEN1101) in Focal onset seizures: Generic, brand name and therapeutic class of product
Published: 2026-09-21T21:41:53-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

4 evidence topics · 4 sources

Manufacturer: Xenon Pharmaceuticals

“Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression.” (opens the source at this quote in a new tab)

Development history and prior product codes

“Originally described in a patent by Valeant Pharmaceuticals in 2008, azetukalner was acquired by First-Order Pharmaceuticals in 2015 and later obtained by Xenon Pharmaceuticals in 2017. It was formerly known as encukalner, XEN1101, 1OP-2198, or VRX621698” (opens the source at this quote in a new tab)

Therapeutic class: KV7 potassium channel opener

“Azetukalner is a novel, potent KV7 potassium channel opener currently in development for the treatment of epilepsy, major depressive disorder and bipolar depression. It represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development.” (opens the source at this quote in a new tab)

Molecular target and seizure type addressed

“XEN1101 is a novel, small-molecule, selective Kv7.2/Kv7.3 potassium channel opener being developed for the treatment of FOSs, the most common type of seizures experienced by individuals with epilepsy.” (opens the source at this quote in a new tab)

Brand name

No evidence found.